Clinical Trial Update: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MK-4830 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors has completed (MK-4830-001).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MK-4830 (MK-4830)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms | Phase 1 | Status: COMPLETED